US equities
|
MU
$931.24
▲+1.87%
NVDA
$217.23
▼-1.84%
SNDK
$1,394.83
▼-0.61%
AMD
$562.23
▼-1.50%
SPCX
$148.62
▼-2.33%
INTC
$95.37
▼-2.80%
AAPL
$342.00
▼-0.28%
MSFT
$539.44
▲+1.08%
MU
$931.24
▲+1.87%
NVDA
$217.23
▼-1.84%
SNDK
$1,394.83
▼-0.61%
AMD
$562.23
▼-1.50%
SPCX
$148.62
▼-2.33%
INTC
$95.37
▼-2.80%
AAPL
$342.00
▼-0.28%
MSFT
$539.44
▲+1.08%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Alkermes plc - Ordinary Shares
(NQ:
ALKS
)
40.10
+1.02 (+2.61%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alkermes plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
October 13, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
September 21, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
September 16, 2026
From
Alkermes plc
Via
Business Wire
Alkermes (NASDAQ:ALKS) Reports Quality Earnings Beat but Stock Falls on Lack of Guidance
↗
July 28, 2026
Via
Chartmill
Topics
Earnings
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss
↗
May 05, 2026
Via
Chartmill
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
September 10, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
↗
August 29, 2026
The insider still has significant holdings in the company, signaling confidence.
Via
The Motley Fool
Topics
Regulatory Compliance
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
August 24, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential
↗
April 29, 2026
Via
Chartmill
Alkermes Q2 Earnings Call Highlights
↗
July 28, 2026
Alkermes (NASDAQ:ALKS) reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following...
Via
MarketBeat
Topics
Earnings
Alkermes plc Reports Second Quarter 2026 Financial Results
July 28, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Report Second Quarter Financial Results on July 28, 2026
July 14, 2026
From
Alkermes plc
Via
Business Wire
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
July 13, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
June 17, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
June 15, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
↗
June 10, 2026
Alkermes (NASDAQ:ALKS) executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for...
Via
MarketBeat
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
June 04, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 03, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
May 26, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
May 21, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
May 12, 2026
From
Alkermes plc
Via
Business Wire
Alkermes (ALKS) Q1 2026 Earnings Transcript
↗
May 05, 2026
Alkermes (ALKS) Q1 2026 Earnings Transcript
Via
The Motley Fool
Alkermes plc Reports First Quarter 2026 Financial Results
May 05, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Report First Quarter Financial Results on May 5, 2026
April 21, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
April 16, 2026
From
Alkermes plc
Via
Business Wire
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
April 14, 2026
From
Alkermes plc
Via
Business Wire
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
April 06, 2026
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...
Via
MarketMinute
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
April 01, 2026
From
Alkermes plc
Via
Business Wire
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
March 31, 2026
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
March 12, 2026
From
Alkermes plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
